No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Jiahe Biological-B (06998.HK): somerley cap has been appointed as the independent financial advisor.
On November 26, Glorious News announced that the board of directors of Jiahe Biological-B (06998.HK) is pleased to announce that Somerley Cap, a corporation licensed to conduct regulated activities under the Securities and Futures Ordinance for Type 1 (trade in securities) and Type 6 (advising on corporate finance), has been appointed as an independent financial advisor to provide advice on (i) the retention plan for Wong and the voting actions of the Listing Rules Independent Board Committee and independent shareholders; and (ii) the proposed merger, cleansing exemption, and shareholder personnel retention plan (including Wong's retention plan) as well as the voting actions before the Takeovers Code Independent Board Committee.
Jiahe Biology-B (06998) has appointed somerley cap as its independent financial advisor.
Jiahua Biotechnology-B (06998) announced that Somerley Cap Limited (a company licensed under the Securities and Futures Ordinance to...)
Due to restricted share units received, Genor Biopharma-B (06998) issued 0.125 million shares.
Jahwa Biological-B (06998) announced that on October 28, 2024, the company selected participants for...
No Data
